1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 7, 17/Feb/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Despite high COVID-19 vaccine coverage in the EU/EEA, there are increasing reports of SARS-CoV-2 infections and hospitalisations in vaccinated individuals. Using surveillance data from Estonia, Ireland, Luxembourg and Slovakia (January–November 2021), we estimated risk reduction of severe outcomes in vaccinated cases. Increasing age remains the most important driver of severity, and vaccination significantly reduces risk in all ages for hospitalisation (adjusted relative risk (aRR): 0.32; 95% confidence interval (CI): 0.26–0.39) and death (aRR: 0.20; 95% CI: 0.13–0.29).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.7.2200060
2022-02-17
2024-12-22
/content/10.2807/1560-7917.ES.2022.27.7.2200060
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/7/eurosurv-27-7-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.7.2200060&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. Stockholm: ECDC; 11 Nov 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans
  2. European Centre for Disease Prevention Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. Stockholm: ECDC; 23 Sep 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Overview-of-the-implementation-of-COVID-19-vaccination-strategies-and-deployment-plans-23-Sep-2021.pdf
  3. Nicolay N, Innocenti F, Beauté J, Učakar V, Grgič Vitek M, Poukka E, et al. Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021. Euro Surveill. 2021;26(48).  https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101030  PMID: 34857068 
  4. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47).  https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101021  PMID: 34823641 
  5. European Centre for Disease Prevention Control (ECDC). Assessment of the current SARS-CoV-2 epidemiological situation in the EU/EEA, projections for the end-of-year festive season and strategies for response, 17th update. Stockholm: ECDC; 24 Nov 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-SARS-CoV-2-17th-update-Nov-2021.pdf
  6. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178.  https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178  PMID: 32156327 
  7. European Centre for Disease Prevention Control (ECDC). Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. Stockholm: ECDC. [Accessed: 14 Feb 2022]. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
  8. European Centre for Disease Prevention Control (ECDC). COVID-19 vaccine tracker. Stockholm: ECDC. [Accessed: 10 Feb 2022 ]. Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
  9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  10. Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021;12(1):6379.  https://doi.org/10.1038/s41467-021-26672-3  PMID: 34737312 
  11. Harder T, Külper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021;26(41).  https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920  PMID: 34651577 
Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Gaetano+Marrone&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Marrone Gaetano</a>, <a href="/search?value1=Nathalie+Nicolay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nicolay Nathalie</a>, <a href="/search?value1=Nick+Bundle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bundle Nick</a>, <a href="/search?value1=Tommi+Karki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Karki Tommi</a>, <a href="/search?value1=Gianfranco+Spiteri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Spiteri Gianfranco</a>, <a href="/search?value1=Heleene+Suija&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Suija Heleene</a>, <a href="/search?value1=Kerstin-Gertrud+K%C3%A4rblane&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kärblane Kerstin-Gertrud</a>, <a href="/search?value1=Jo%C3%ABl+Mossong&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mossong Joël</a>, <a href="/search?value1=Anne+Vergison&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vergison Anne</a>, <a href="/search?value1=Maria+Avdicova&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Avdicova Maria</a>, <a href="/search?value1=Adriana+Mecochova&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mecochova Adriana</a>, <a href="/search?value1=Gillian+Cullen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cullen Gillian</a>, <a href="/search?value1=Piaras+O%E2%80%99Lorcain&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’Lorcain Piaras</a>, <a href="/search?value1=Lucia+Pastore+Celentano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Celentano Lucia Pastore</a>, <a href="/search?value1=Tarik+Derrough&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Derrough Tarik</a>, <a href="/search?value1=Julien+Beaut%C3%A9&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Beauté Julien</a></span>. Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(7):pii=2200060. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.7.2200060" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.7.2200060</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 19 Jan 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 Feb 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.7.2200060
/content/10.2807/1560-7917.ES.2022.27.7.2200060
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error